Lilly investors got the jitters, saw better opportunities elsewhere, or decided to hold onto their chips. In the third ...

Mindy McCormick, 67, read that her insurer would soon stop covering the weight loss drug Wegovy, which she had been taking for more than two years. Nearly 9,000 people across the state had received ...

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

Results for its new CagriSema drug, while promising, fell below expectations, sending shares of the pharmaceutical giant down ...

Novo Nordisk (NVO) increased valuation gap with Eli Lilly (LLY) after its Phase 3 data for next-gen weight loss drug ...

Illustration: Elizabeth Smelov Novo Nordisk shares dived Friday after an experimental anti-obesity treatment missed ...

Novo Nordisk, Europe’s largest company by market value, faced a stock market bloodbath on Friday after disappointing results ...

Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently ...

Investors and analysts had eagerly awaited this data as a test of Novo’s case that it has a strong pipeline of drugs to ...

New clinical trial data from Novo Nordisk raise questions for the broad landscape of obesity drug development and the way ...

The competition between Eli Lilly and Novo Nordisk, makers of Zepbound and Wegovy, reflects the growing interest in the weight loss drug market. Currently, Novo Nordisk leads with Wegovy ...